On Friday, Neonode, Inc. (NASDAQ:NEON)’s shares gained 2.79% to $4.05, while its weekly performance remained better, showing an upward trend up to 18.77%.
Formerly on March 12, Neonode stated financial results for the fourth quarter and year ended December 31, 2014.
Financial Results for the Fourth Quarter of 2014:
Fourth quarter 2014 merged net proceeds raised 54% to $1.7 million contrast to $1.1 million for the third quarter of 2014. On a year-over-year basis, fourth quarter 2014 proceeds raised by 72%, primarily due to raised license fees and NRE fees earned from accomplished development projects.
Operating expenses raised 13% to $4.3 million for the fourth quarter of 2014 contrast to $3.8 million for the same quarter in 2013 due to several factors counting legal expense related to patent filings and non-recurring events, an raise in headcount, primarily in our sales and engineering departments due to raised activities in the automotive, printer and PC segments. Merged fourth quarter net loss was $3.1 million or $0.08 loss per share, contrast with a net loss of $3.0 million or $0.08 loss per share for the comparable quarter in 2013.
Neonode Inc., together with its auxiliaries, develops and licenses user interfaces and optical infrared touch technology solutions in the United States, Japan, China, Taiwan, South Korea, Italy, Sweden, and internationally.
iBio, Inc. (NYSEMKT:IBIO)’s shares dropped -14.29% to $0.90, during the last trading session on Friday, while its weekly performance remained Best, showing an upward trend up to 18.42%.
Formerly on March 30, iBio declared it received notice from the European Patent Office that the opposition period expired for a bio-defense product patent granted to iBio, and no opposition was filed.
The patent, entitled “Yersinia Pestis Antigens, Vaccine Compositions and Related Methods” (European patent EP 2178558), comprises claims covering plague antigens fused to a thermostable protein such as the Company’s iBioModulator ™ thermostable immunomodulator, in addition to vaccine compositions and a method for producing the antigen.
“This is an important extension of our commercial platform,” said Robert Erwin, iBio’s president. “We expect our success with vaccine and therapeutic product candidates for use against serious infectious disease agents with weapon potential, such as plague bacillus, to be of interest to governments and companies engaged in supplying disease countermeasures.”
iBio, Inc., a biotechnology company, focuses on the commercialization of its proprietary plant-based protein expression technologies in the United States and internationally. Its proprietary technologies comprise iBioLaunch, a transformative platform technology for the development and production of therapeutic proteins and vaccines; and iBioModulator, a technology platform that enhances the potency and duration of the effect of prophylactic and therapeutic vaccines.
At the end of Friday’s trade, Silicon Motion Technology Corp. (NASDAQ:SIMO)’s shares dipped -0.90% to $31.96, hitting its highest level, while its weekly performance remained Best, showing an upward trend up to 18.28%.
Silicon Motion, declared that based upon its preliminary first quarter financial results, proceed is predictable to be roughly flat sequentially, at the high-end of its original guidance range of a sequential decline of 5% to 0% that the company issued on January 27, 2015. Gross margin (non-GAAP) is predictable to be within 51 to 52%, at the high-end of the company’s original guidance range of 50 to 52%.
The Company will release its full first quarter 2015 results after the market closes on April 27, 2015. The Company will host a conference call on April 28, at 8 am Eastern Time, to talk about its results.
Silicon Motion Technology Corporation, a fabless semiconductor company, designs, develops, and markets semiconductor solutions for mobile storage and mobile communications markets. It provides mobile storage products, counting microcontrollers used in solid state storage devices, such as solid state drives, eMMCs, and other embedded flash applications, in addition to removable storage products, such as flash memory card controllers and USB flash drive controllers; and mobile communications products, such as mobile TV SoCs and handset transceivers.
CAMAC Energy, Inc. (NYSEMKT:CAK), ended its Friday’s trading session with 6.58% gain, and closed at $0.77, while its weekly performance remained better, showing an upward trend up to 18.06%.
Formerly on March 31, CAMAC Energy declared it has finished completion operations on the Oyo-8 well, located offshore Nigeria, and is now ready to commence oil production.
Oyo-8 is hooked up to the FPSO Armada Perdana owned by Bumi Armada Berhad. However, CAMAC has been informed by Bumi that the FPSO is not ready to receive oil production from the well due to class certification inspections of the vessel’s mooring lines being conducted by the American Bureau of Shipping. Bumi estimates these inspections to be accomplished within two weeks, at which time Oyo-8 will be allowed to produce into the FPSO.
In the meantime, CAMAC is demobilizing the Sedco Express drilling rig from the Oyo-8 location and the rig will then mobilize to the Oyo-6 well location to continue its planned Oyo field operations. The Company does not anticipate further changes to the project plan of the Oyo-7 well as a result of the FPSO inspection delays.
CAMAC Energy Inc. operates as an independent oil and gas exploration and production company focused on energy resources in Africa. Its asset portfolio comprises of nine licenses covering an area of 43,000 square kilometers, counting production and exploration properties offshore Nigeria; and exploration licenses offshore Ghana, Kenya, and Gambia, in addition to onshore Kenya.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
